Amyloid-Beta: A Crucial Factor in Alzheimer's Disease

Alzheimer's disease (AD) is the most prevalent form of dementia which affects people older than 60 years of age. In AD, the dysregulation of the amyloid-beta (Aβ) level leads to the appearance of senile plaques which contain Aβ depositions. Aβ is a complex biological molecule which interacts with many types of receptors and/or forms insoluble assemblies and, eventually, its nonphysiological depositions alternate with the normal neuronal conditions. In this situation, AD signs appear and the patients experience marked cognitional disabilities. In general, intellect, social skills, personality, and memory are influenced by this disease and, in the long run, it leads to a reduction in quality of life and life expectancy. Due to the pivotal role of Aβ in the pathobiology of AD, a great deal of effort has been made to reveal its exact role in neuronal dysfunctions and to finding efficacious therapeutic strategies against its adverse neuronal outcomes. Hence, the determination of its different molecular assemblies and the mechanisms underlying its pathological effects are of interest. In the present paper, some of the well-established structural forms of Aβ, its interactions with various receptors and possible molecular and cellular mechanisms underlying its neurotoxicity are discussed. In addition, several Aβ-based rodent models of AD are reviewed.

[1]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[2]  이정은.  Analysis of differential plaque depositions in the brains of Tg2576 and Tg-APPswe/PS1∆E9 transgenic mouse models of Alzheimer disease , 2013 .

[3]  H. Loetscher,et al.  Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β. , 2012, Journal of Alzheimer's disease : JAD.

[4]  G. Forloni,et al.  The neurodegeneration in Alzheimer disease and the prion protein , 2013, Prion.

[5]  W. K. Cullen,et al.  Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.

[6]  M. Bresjanac,et al.  TAU PROTEIN AND HUMAN TAUOPATHIES: AN OVERWIEV* , 2008 .

[7]  L. Mucke,et al.  Amyloid-β–induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks , 2010, Nature Neuroscience.

[8]  Ilya Bezprozvanny,et al.  Role of endoplasmic reticulum Ca2+ signaling in the pathogenesis of Alzheimer disease , 2013, Front. Mol. Neurosci..

[9]  I. Chatterjee,et al.  Targeting tau oligomers for therapeutic development for Alzheimer's disease and tauopathies , 2008 .

[10]  Jürgen Götz,et al.  Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models , 2010, Cell.

[11]  E. Masliah,et al.  Transgenic animal models of neurodegenerative diseases and their application to treatment development. , 2007, Advanced drug delivery reviews.

[12]  Hyoung-Gon Lee,et al.  Neuropathology in Alzheimer's disease: awaking from a hundred-year-old dream. , 2006, Science of aging knowledge environment : SAGE KE.

[13]  P. Wong,et al.  Amyloid precursor protein processing and Alzheimer's disease. , 2011, Annual review of neuroscience.

[14]  L. Reijmers,et al.  Natural Amyloid-Beta Oligomers Acutely Impair the Formation of a Contextual Fear Memory in Mice , 2012, PloS one.

[15]  D. Holtzman,et al.  Neuronal Clearance of Amyloid-β by Endocytic Receptor LRP1 , 2013, The Journal of Neuroscience.

[16]  Eric J Topol,et al.  Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins , 2004, The Lancet.

[17]  J. Rosales,et al.  Viewpoint: Crosstalks between neurofibrillary tangles and amyloid plaque formation , 2013, Ageing Research Reviews.

[18]  D. Butterfield,et al.  Amyloid β‐Peptide(1‐42) Contributes to the Oxidative Stress and Neurodegeneration Found in Alzheimer Disease Brain , 2004, Brain pathology.

[19]  G. Elder,et al.  Transgenic mouse models of Alzheimer's disease. , 2010, The Mount Sinai journal of medicine, New York.

[20]  Kang Hu,et al.  High-Level Neuronal Expression of Aβ1–42 in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation , 2000, The Journal of Neuroscience.

[21]  J. Attems,et al.  Capillary CAA and perivascular Aβ-deposition: Two distinct features of Alzheimer's disease pathology , 2010, Journal of the Neurological Sciences.

[22]  M. Szyf,et al.  A novel transgenic rat model with a full Alzheimer's-like amyloid pathology displays pre-plaque intracellular amyloid-beta-associated cognitive impairment. , 2010, Journal of Alzheimer's disease : JAD.

[23]  J. Hardy,et al.  Aβ42 Is Essential for Parenchymal and Vascular Amyloid Deposition in Mice , 2005, Neuron.

[24]  W. Shen,et al.  Amyloid β42 Activates a G-Protein-Coupled Chemoattractant Receptor, FPR-Like-1 , 2001, The Journal of Neuroscience.

[25]  E. Mufson,et al.  Cholinotrophic basal forebrain system alterations in 3xTg-AD transgenic mice , 2011, Neurobiology of Disease.

[26]  Mark T. W. Ebbert,et al.  Genetics of Alzheimer's Disease , 2013, BioMed research international.

[27]  C. Parsons,et al.  Alzheimer's disease, β‐amyloid, glutamate, NMDA receptors and memantine – searching for the connections , 2012, British journal of pharmacology.

[28]  T. Wisniewski,et al.  The Innate Immune System in Alzheimer's Disease , 2013, International journal of cell biology.

[29]  C. Cotman,et al.  Structure‐Activity Analyses of β‐Amyloid Peptides: Contributions of the β25–35 Region to Aggregation and Neurotoxicity , 1995 .

[30]  M. Kivipelto,et al.  Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention , 2009, Dialogues in clinical neuroscience.

[31]  D. Galimberti,et al.  The Role of the Innate Immune System in Alzheimer's Disease and Frontotemporal Lobar Degeneration: An Eye on Microglia , 2013, Clinical & developmental immunology.

[32]  W. Klein,et al.  Different β-amyloid oligomer assemblies in Alzheimer brains correlate with age of disease onset and impaired cholinergic activity , 2012, Neurobiology of Aging.

[33]  F. LaFerla,et al.  Pathways by which Abeta facilitates tau pathology. , 2006, Current Alzheimer research.

[34]  L. Goldstein,et al.  Disruption of Axonal Transport and Neuronal Viability by Amyloid Precursor Protein Mutations in Drosophila , 2001, Neuron.

[35]  M. Mattson,et al.  Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles Intracellular Aβ and Synaptic Dysfunction , 2003, Neuron.

[36]  R. Katzman.,et al.  Modulation of amyloid beta-protein clearance and Alzheimer's disease susceptibility by the LDL receptor-related protein pathway. , 2000, The Journal of clinical investigation.

[37]  Bernardo L Sabatini,et al.  Natural Oligomers of the Alzheimer Amyloid-β Protein Induce Reversible Synapse Loss by Modulating an NMDA-Type Glutamate Receptor-Dependent Signaling Pathway , 2007, The Journal of Neuroscience.

[38]  M. Frotscher,et al.  Low Density Lipoprotein Receptor-related Protein 1 (LRP1) Modulates N-Methyl-d-aspartate (NMDA) Receptor-dependent Intracellular Signaling and NMDA-induced Regulation of Postsynaptic Protein Complexes* , 2013, The Journal of Biological Chemistry.

[39]  Ronald Melki,et al.  Prion-like transmission of protein aggregates in neurodegenerative diseases , 2010, Nature Reviews Molecular Cell Biology.

[40]  D. Selkoe,et al.  Soluble oligomers of the amyloid β-protein impair synaptic plasticity and behavior , 2008, Behavioural Brain Research.

[41]  J. Pierce,et al.  Innate immunity receptor CD36 promotes cerebral amyloid angiopathy , 2013, Proceedings of the National Academy of Sciences.

[42]  J Korf,et al.  β‐Amyloid neurotoxicity is mediated by a glutamate‐triggered excitotoxic cascade in rat nucleus basalis , 2000, The European journal of neuroscience.

[43]  A. Takashima,et al.  Hyperphosphorylated tau in parahippocampal cortex impairs place learning in aged mice expressing wild‐type human tau , 2007, The EMBO journal.

[44]  M. Khatami.  Inflammatory Diseases - Immunopathology, Clinical and Pharmacological Bases , 2012 .

[45]  Huadong Zhou,et al.  Clearance of amyloid-beta in Alzheimer's disease: progress, problems and perspectives. , 2006, Drug discovery today.

[46]  M. Fitzgerald,et al.  Effect of acid predissolution on fibril size and fibril flexibility of synthetic beta-amyloid peptide. , 1994, Biophysical journal.

[47]  J. Götz,et al.  Animal models of Alzheimer's disease and frontotemporal dementia , 2008, Nature Reviews Neuroscience.

[48]  M. Rowan,et al.  Alzheimer's Disease Brain-Derived Amyloid-β-Mediated Inhibition of LTP In Vivo Is Prevented by Immunotargeting Cellular Prion Protein , 2011, The Journal of Neuroscience.

[49]  D. Walsh,et al.  Alzheimer's disease: synaptic dysfunction and Aβ , 2009, Molecular Neurodegeneration.

[50]  C. Link,et al.  Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[51]  A. Fagan,et al.  P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. , 2005, The Journal of clinical investigation.

[52]  S. Shimohama,et al.  Alzheimer's disease and acetylcholine receptors. , 2004, Acta neurobiologiae experimentalis.

[53]  Roger M. Nitsch,et al.  Intracellular Aβ and cognitive deficits precede β-amyloid deposition in transgenic arcAβ mice , 2007, Neurobiology of Aging.

[54]  D. Holtzman,et al.  Amyloid‐beta oligomerization in Alzheimer dementia versus high‐pathology controls , 2013, Annals of neurology.

[55]  Mehdi Farhoudi,et al.  Association of apolipoprotein E epsilon 4 allele with sporadic late onset Alzheimer`s disease. A meta-analysis. , 2012, Neurosciences.

[56]  N. Hooper,et al.  Prion Protein-mediated Toxicity of Amyloid-β Oligomers Requires Lipid Rafts and the Transmembrane LRP1* , 2013, The Journal of Biological Chemistry.

[57]  D. Selkoe,et al.  Soluble amyloid β-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration , 2011, Proceedings of the National Academy of Sciences.

[58]  G. Collingridge,et al.  Microtubule-associated protein tau is essential for long-term depression in the hippocampus , 2014, Philosophical Transactions of the Royal Society B: Biological Sciences.

[59]  M. Sorgato,et al.  Prions and Prion-Like Pathogens in Neurodegenerative Disorders , 2014, Pathogens.

[60]  M. Graham.  Clinical Molecular Imaging with Radiotracers: Current Status , 2011, Medical Principles and Practice.

[61]  Patrick R. Hof,et al.  Tau protein isoforms, phosphorylation and role in neurodegenerative disorders 1 1 These authors contributed equally to this work. , 2000, Brain Research Reviews.

[62]  Yuan Cheng,et al.  From fragment screening to in vivo efficacy: optimization of a series of 2-aminoquinolines as potent inhibitors of beta-site amyloid precursor protein cleaving enzyme 1 (BACE1). , 2011, Journal of medicinal chemistry.

[63]  B. Hyman,et al.  Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[64]  T. Kubo,et al.  In vivo conversion of racemized β‐amyloid ([D‐Ser26]Aβ1–40) to truncated and toxic fragments ([D‐Ser26]Aβ25–35/40) and fragment presence in the brains of Alzheimer's patients , 2002 .

[65]  R. Anwyl,et al.  Use-Dependent Effects of Amyloidogenic Fragments of β-Amyloid Precursor Protein on Synaptic Plasticity in Rat Hippocampus In Vivo , 2001, The Journal of Neuroscience.

[66]  J. Brion,et al.  Neurofibrillary Tangles and Alzheimer’s Disease , 1998, European Neurology.

[67]  S. Sadigh-Eteghad,et al.  Different patterns of brain activation in normal aging and Alzheimer's disease from cognitional sight: meta analysis using activation likelihood estimation , 2014, Journal of the Neurological Sciences.

[68]  A. Nordberg.  Amyloid plaque imaging in vivo: current achievement and future prospects , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[69]  Yanjue Wu,et al.  Transgenic C. elegans as a model in Alzheimer's research. , 2005, Current Alzheimer research.

[70]  M. Folstein,et al.  Insulin, insulin-degrading enzyme and amyloid-β peptide in Alzheimer's disease: review and hypothesis , 2006, Neurobiology of Aging.

[71]  S. Younkin,et al.  Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.

[72]  Nicolas Cherbuin,et al.  A Self-Report Risk Index to Predict Occurrence of Dementia in Three Independent Cohorts of Older Adults: The ANU-ADRI , 2014, PloS one.

[73]  D. Selkoe,et al.  The cell biology of β-amyloid precursor protein and presenilin in Alzheimer's disease , 1998 .

[74]  P. Scheltens,et al.  Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.

[75]  D. Westaway,et al.  Transgenic mouse models of Alzheimer's disease , 2001, Physiology & Behavior.

[76]  David H. Cribbs,et al.  Aβ Immunotherapy Leads to Clearance of Early, but Not Late, Hyperphosphorylated Tau Aggregates via the Proteasome , 2004, Neuron.

[77]  George Perry,et al.  Mitochondrial dysfunction is a trigger of Alzheimer's disease pathophysiology. , 2010, Biochimica et biophysica acta.

[78]  K. Lunetta,et al.  The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease , 2007, Nature Genetics.

[79]  R. Vassar,et al.  Molecular Neurodegeneration BioMed Central Review The Alzheimer's disease β-secretase enzyme, BACE1 , 2007 .

[80]  M. Goedert,et al.  Somatodendritic localization and hyperphosphorylation of tau protein in transgenic mice expressing the longest human brain tau isoform. , 1995, The EMBO journal.

[81]  N. Maleki-Dizaji,et al.  Investigation of the Memory Impairment in Rats Fed with Oxidized-Cholesterol-Rich Diet Employing Passive Avoidance Test , 2014, Drug Research.

[82]  G. Logroscino,et al.  Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies. , 2012, Immunotherapy.

[83]  D. Selkoe.  The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease. , 1998, Trends in cell biology.

[84]  S. Love,et al.  Endothelin-converting enzyme-2 is increased in Alzheimer's disease and up-regulated by Abeta. , 2009, The American journal of pathology.

[85]  M. Gobbi,et al.  Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein , 2010, Proceedings of the National Academy of Sciences.

[86]  D. Westaway,et al.  Amyloid-β-(1-42) Increases Ryanodine Receptor-3 Expression and Function in Neurons of TgCRND8 Mice* , 2006, Journal of Biological Chemistry.

[87]  M. Miyazaki,et al.  Protective Effects of Rosa damascena and Its Active Constituent on Aβ(25–35)-Induced Neuritic Atrophy , 2011, Evidence-based complementary and alternative medicine : eCAM.

[88]  S. Sadigh-Eteghad,et al.  Beta-amyloid exhibits antagonistic effects on alpha 7 nicotinic acetylcholine receptors in orchestrated manner , 2014 .

[89]  D. Selkoe,et al.  Effects of secreted oligomers of amyloid β‐protein on hippocampal synaptic plasticity: a potent role for trimers , 2006, The Journal of physiology.

[90]  M. Ohno,et al.  Intraneuronal β-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential Factors in Amyloid Plaque Formation , 2006, The Journal of Neuroscience.

[91]  L. Mucke,et al.  Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein , 1995, Nature.

[92]  Daniel N. Hill,et al.  Staged decline of neuronal function in vivo in an animal model of Alzheimer's disease , 2012, Nature Communications.

[93]  B. Winblad,et al.  Progressive neuropathology and cognitive decline in a single Arctic APP transgenic mouse model , 2011, Neurobiology of Aging.

[94]  M. Masserini,et al.  TrkA pathway activation induced by amyloid-beta (Abeta) , 2009, Molecular and Cellular Neuroscience.

[95]  Shaomin Li,et al.  Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory , 2008, Nature Medicine.

[96]  M. Kirkitadze,et al.  Molecular mechanisms initiating amyloid beta-fibril formation in Alzheimer's disease. , 2005, Acta biochimica Polonica.

[97]  Yama Akbari,et al.  Age- and region-dependent alterations in Aβ-degrading enzymes: implications for Aβ-induced disorders , 2005, Neurobiology of Aging.

[98]  F. Çetin,et al.  The Effect of Intrahippocampal Beta Amyloid (1‐42) Peptide Injection on Oxidant and Antioxidant Status in Rat Brain , 2007, Annals of the New York Academy of Sciences.

[99]  S. Sadigh-Eteghad,et al.  Association of apolipoprotein E epsilon 4 allele with sporadic late onset Alzheimer's disease , 2012 .

[100]  Peter B. Reiner,et al.  β‐Amyloid efflux mediated by p‐glycoprotein , 2001 .

[101]  A. Vortmeyer,et al.  Alzheimer Amyloid-β Oligomer Bound to Post-Synaptic Prion Protein Activates Fyn to Impair Neurons , 2012, Nature Neuroscience.

[102]  S. Arlt,et al.  Amyloid-β is an antioxidant for lipoproteins in cerebrospinal fluid and plasma , 2001 .

[103]  H. Lester,et al.  Persistent Amyloidosis following Suppression of Aβ Production in a Transgenic Model of Alzheimer Disease , 2005, PLoS medicine.

[104]  M. Rowan,et al.  A monoclonal antibody against synthetic Aβ dimer assemblies neutralizes brain‐derived synaptic plasticity‐disrupting Aβ , 2011, Journal of neurochemistry.

[105]  Ping Xu,et al.  The Loss of c-Jun N-Terminal Protein Kinase Activity Prevents the Amyloidogenic Cleavage of Amyloid Precursor Protein and the Formation of Amyloid Plaques In Vivo , 2011, The Journal of Neuroscience.

[106]  G. Landreth,et al.  Evidence for impaired amyloid β clearance in Alzheimer's disease , 2013, Alzheimer's Research & Therapy.

[107]  M. Goedert,et al.  A Century of Alzheimer's Disease , 2006, Science.

[108]  D. Ciraulo.  Neuropsychopharmacology: The Fifth Generation of Progress , 2003 .

[109]  R. Deane,et al.  Early-onset and Robust Cerebral Microvascular Accumulation of Amyloid β-Protein in Transgenic Mice Expressing Low Levels of a Vasculotropic Dutch/Iowa Mutant Form of Amyloid β-Protein Precursor* , 2004, Journal of Biological Chemistry.

[110]  F. Schmidt.  Meta-Analysis , 2008 .

[111]  K. Duff,et al.  Transgenic mouse models of Alzheimer's disease: how useful have they been for therapeutic development? , 2004, Briefings in functional genomics & proteomics.

[112]  M. Di Carlo.  Simple model systems: a challenge for Alzheimer's disease , 2012, Immunity & Ageing.

[113]  W. Gong,et al.  Amyloid (beta)42 activates a G-protein-coupled chemoattractant receptor, FPR-like-1. , 2001, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[114]  M. Findeis.  The role of amyloid β peptide 42 in Alzheimer's disease , 2007 .

[115]  A. Koudinov,et al.  Alzheimer's amyloid-beta (A beta) is an essential synaptic protein, not neurotoxic junk. , 2004, Acta neurobiologiae experimentalis.

[116]  G. Bu,et al.  The low-density lipoprotein receptor-related protein 1 and amyloid-β clearance in Alzheimer’s disease , 2014, Front. Aging Neurosci..